Last reviewed · How we verify
NCT07461675
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
Phase 3 trial testing Atezolizumab in Hepato Cellular Carcinoma (HCC) in 30 participants. Not yet recruiting.
1 June 2029
Quick facts
| Lead sponsor | University of Geneva, Switzerland |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 25 March 2026 |
| Primary completion | 1 June 2029 |
| Estimated completion | 31 December 2029 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Atezolizumab (atezolizumab) — full drug profile →
Conditions studied
- Hepato Cellular Carcinoma (HCC) — all drugs for Hepato Cellular Carcinoma (HCC) →
- Immunotherapy — all drugs for Immunotherapy →
Sponsor
University of Geneva, Switzerland
Who can join
18 and older, any sex, with Hepato Cellular Carcinoma (HCC) or Immunotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our study aims to evaluate the benefit of the administration of immunotherapy (atezolizumab), in patients with hepatocellular carcinoma (HCC), prior surgical resection of the tumor. HCC is the most prevalent primary liver cancer, responsible for nearly 800,000 deaths annually, making it the third leading cause of cancer-related mortality worldwide. Ablation by radiologic micro-waves or surgical resection represent at the moment the only curative therapies for early stages of the disease. Despite these curative options, HCC recurrence is frequent. Recently, immunotherapy has demonstrated good results on patient overall survival for advanced stages of HCC in comparison to sorafenib. Because of the beneficial effect of immunotherapy on HCC, several groups have attempt to use it as adjuvant therapy in order to reduce the recurrence rate. However the results are at the moment controversial. One can hypothetize that postoperative inflammation and liver regeneration can negatively impact the effect of the immunotherapy. Therefore, the administration of the treatmeent before surgical resection could overcome this issue.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07461675
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Atezolizumab
Trials testing the same drug.
- NCT07388524 — Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer · Phase 3 · not yet recruiting
- NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
- NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting
- NCT07166406 — Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO- · Phase 3 · recruiting
Other recruiting trials for Hepato Cellular Carcinoma (HCC)
Currently open trials in the same condition.
- NCT07276100 — Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With Atezoli · Phase 2 · recruiting
- NCT06990659 — Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC) · NA · recruiting
- NCT06960863 — Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma · recruiting
- NCT06960954 — PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma · recruiting
- NCT06812039 — HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients · Phase 2 · recruiting
Other University of Geneva, Switzerland trials
Trials by the same sponsor.
- NCT07345858 — Salivary Oxytocin as a Biomarker of Psychedelic Treatment · enrolling by invitation
- NCT07072338 — Promoting Mental and Cognitive Health in Old Age Through Scalable Evidence-based Interventions · NA · not yet recruiting
- NCT06191835 — Implementation of a New Model of Care for Supporting Long-term Medication Adherence (Phase A) · active not recruiting
- NCT05966623 — Assessing the Impact of Vidéo Remote Sign Language Interpreting in Healthcare · NA · unknown
- NCT06114147 — Cardiac Flow Measurements in Pregnant Women by Non Invasive Techniques · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07461675 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Geneva, Switzerland
- Last refreshed: 10 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07461675.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing